ARTICLE
14 January 2026

Healthcare Trends & Transactions: 2025 Year In Review

BB
Bass, Berry & Sims

Contributor

Bass, Berry & Sims is a national law firm with nearly 350 attorneys dedicated to delivering exceptional service to numerous publicly traded companies and Fortune 500 businesses in significant litigation and investigations, complex business transactions, and international regulatory matters. For more than 100 years, our people have served as true partners to clients, working seamlessly across substantive practice disciplines, industries and geographies to deliver highly-effective legal advice and innovative, business-focused solutions. For more information, visit www.bassberry.com.
At the end of 2024, we predicted that the healthcare mergers and acquisitions market would pick up steam in 2025 given the combination of decreasing interest rates, a potential shift in the regulatory landscape with the new presidential administration and growing comfort and familiarity.
United States Food, Drugs, Healthcare, Life Sciences
Bass, Berry & Sims are most popular:
  • within Coronavirus (COVID-19) topic(s)
  • with readers working within the Healthcare and Construction & Engineering industries

At the end of 2024, we predicted that the healthcare mergers and acquisitions (M&A) market would pick up steam in 2025 given the combination of decreasing interest rates, a potential shift in the regulatory landscape with the new presidential administration and growing comfort and familiarity with new state reporting requirements related to physician practice management (PPM) and other healthcare transactions. However, the general sentiment appears to be that 2025 was more of the same—a generally steady year from a deal volume standpoint, marked by strong lower middle market activity and some high-dollar, headline-making transactions, such as Ascension entering into a definitive agreement to acquire AmSurg for a reported $3.9 billion, private equity (PE) firm Sycamore Partners' take-private acquisition of Walgreens Boots Alliance for $10 billion, UnitedHealth Group's (NYSE: UNH) successful antitrust approval in its long-running effort to acquire home health and hospice provider Amedisys for $3.3 billion, and Cencora's (NYSE: COR) agreeing to buy out partner TPG's interest in oncology platform OneOncology for $3.6 billion.

That said, a steady healthcare M&A market should be viewed favorably after the tumult and variability of the early 2020s. Moreover, the year seems to have ended on a positive note—early indications are that deal values increased significantly from Q3 to Q4 of 2025.

Below are some of the notable healthcare transactions announced or closed in 2025 within the following sectors:

  • Physician Practice Management
  • Clinical Research Organizations
  • Ambulatory Surgery Centers
  • Hospitals & Health Systems
  • Home Health, Hospice & Personal Care Services
  • Managed Care
  • Digital Health & Health Information Technology
  • Pharma Services, Pharmacy & Pharmacy Benefit Managers
  • Behavioral Health

Please click here to view the original article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More